Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.73 |
| ▸ | TFPI | P10646 | 4/20 | 0.68 |
| ▸ | NPY2R | P49146 | 8/20 | 0.67 |
| ▸ | NPY4R | P50391 | 8/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY1R | P25929 | 6/20 | 0.67 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.66 |
| ▸ | CALCR | P30988 | 5/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360080 | 1.00 | CALCA (0.73) | CALCATFPINPY2RNPY4RNPY5R | |
| SCHEMBL29360353 | 0.94 | CALCA (0.73) | CALCATFPINPY2RNPY4RNPY5R | |
| SCHEMBL29210101 | 0.94 | CALCA (0.73) | CALCATFPINPY2RNPY4RNPY5R | |
| SCHEMBL31060662 | 0.94 | CALCA (0.82) | CALCATFPINPY2RNPY4RNPY5R | |
| SCHEMBL29743043 | 0.92 | CALCA (0.65) | CALCATFPINPY2RNPY4RNPY5R | |
| SCHEMBL31251982 | 0.90 | CALCA (0.90) | CALCATFPINPY2RNPY4RNPY5R | |
| Buforin Ii SCHEMBL29378594 | 0.89 | NPY2R (0.71) | TFPINPY2RNPY4RNPY5RNPY1R | |
| Buforin Ii SCHEMBL29357731 | 0.89 | NPY2R (0.71) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29977603 | 0.87 | NPY2R (0.69) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29783625 | 0.87 | CALCR (0.65) | CALCATFPIRAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4585264-A2 | HUMAN CGRP RECEPTOR BINDING PROTEINS | AMGEN INC. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| EP-3569620-B1 | HUMAN CGRP RECEPTOR BINDING ANTIBODIES | AMGEN INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129172-A1 | HUMAN CGRP RECEPTOR BINDING PROTEINS | AMGEN INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-11-07 | — | — | US | disclosed |
| US-12134652-B2 | Human CGRP receptor binding proteins | AMGEN INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12122841-B2 | Human CGRP receptor binding proteins | AMGEN INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240158481-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2024-05-16 | — | — | US | disclosed |
| CN-116063580-A | Peptide analogues | 艾得佩索拉公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | disclosed |
| US-11555064-B2 | Treating headache comprising administering an antibody to calcitonin gene-related peptide | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-01-17 | — | — | US | disclosed |
| US-20220340633-A1 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | ADEPTHERA LLC | 2022-10-27 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-20220249471-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-11 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3242882-B1 | CGRP ANTAGONIST PEPTIDES | FERRING BV (NL) | 2022-05-04 | — | — | EP | disclosed |
| US-20220056114-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555064-B2 | Treating headache comprising administering an antibody to calcitonin gene-related peptide | CALCA, CALCRL, CALCB | CALCA 1/4885TFPI 614/4885NPY2R 176/4885 |
| US-20220340633-A1 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | RAMP1, CALCRL, RAMP3 | CALCA 11/4885TFPI 1913/4885NPY2R 321/4885 |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | OPRL1, CALCRL, CALCR | CALCA 4/4885TFPI 200/4885NPY2R 72/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | CALCA 49/4885TFPI 2625/4885NPY2R 136/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | CALCA 26/4885TFPI 2587/4885NPY2R 156/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | CALCA 26/4885TFPI 2587/4885NPY2R 156/4885 |
| US-20240158481-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | CALCRL, CALCA, CALCB | CALCA 2/4885TFPI 480/4885NPY2R 141/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | CALCA 49/4885TFPI 2625/4885NPY2R 136/4885 |
| US-20220056114-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | CALCRL, CALCA, CALCB | CALCA 2/4885TFPI 480/4885NPY2R 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.